Aspen Aerogels (NYSE:ASPN) Rating Reiterated by HC Wainwright

HC Wainwright restated their buy rating on shares of Aspen Aerogels (NYSE:ASPN) in a research report sent to investors on Wednesday morning, Benzinga reports. They currently have a $30.00 target price on the construction company’s stock.

A number of other equities research analysts have also issued reports on ASPN. Roth Mkm reissued a “buy” rating and set a $36.00 price target on shares of Aspen Aerogels in a research note on Wednesday, August 21st. B. Riley upgraded Aspen Aerogels to a “strong-buy” rating in a research report on Tuesday, June 25th. TD Cowen upped their price target on shares of Aspen Aerogels from $36.00 to $41.00 and gave the stock a “buy” rating in a report on Tuesday, August 20th. Benchmark reissued a “buy” rating and issued a $14.00 price objective on shares of Aspen Aerogels in a research report on Thursday, August 8th. Finally, Barclays started coverage on shares of Aspen Aerogels in a research report on Tuesday, August 6th. They set an “overweight” rating and a $27.00 target price on the stock. One analyst has rated the stock with a sell rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $29.70.

Aspen Aerogels Stock Down 3.7 %

Shares of ASPN opened at $21.60 on Wednesday. The company has a quick ratio of 2.82, a current ratio of 3.46 and a debt-to-equity ratio of 0.23. Aspen Aerogels has a 52-week low of $6.62 and a 52-week high of $33.15. The company has a market cap of $1.65 billion, a PE ratio of -49.09 and a beta of 2.16. The business has a fifty day moving average of $26.00 and a 200 day moving average of $24.40.

Aspen Aerogels (NYSE:ASPN) last released its quarterly earnings results on Wednesday, August 7th. The construction company reported $0.21 EPS for the quarter, topping analysts’ consensus estimates of $0.05 by $0.16. The firm had revenue of $117.80 million during the quarter, compared to analysts’ expectations of $101.99 million. Aspen Aerogels had a net margin of 0.39% and a return on equity of 0.74%. The firm’s revenue for the quarter was up 144.4% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.22) EPS. On average, sell-side analysts expect that Aspen Aerogels will post 0.21 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Donald R. Young sold 63,355 shares of Aspen Aerogels stock in a transaction that occurred on Monday, September 30th. The shares were sold at an average price of $30.03, for a total value of $1,902,550.65. Following the transaction, the chief executive officer now owns 483,640 shares of the company’s stock, valued at $14,523,709.20. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Aspen Aerogels news, CEO Donald R. Young sold 63,355 shares of the firm’s stock in a transaction that occurred on Monday, September 30th. The shares were sold at an average price of $30.03, for a total value of $1,902,550.65. Following the completion of the sale, the chief executive officer now directly owns 483,640 shares in the company, valued at $14,523,709.20. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Ricardo C. Rodriguez sold 32,465 shares of Aspen Aerogels stock in a transaction on Monday, August 26th. The stock was sold at an average price of $30.14, for a total transaction of $978,495.10. Following the completion of the transaction, the chief financial officer now directly owns 20,790 shares in the company, valued at $626,610.60. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.30% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Aspen Aerogels

A number of large investors have recently modified their holdings of the business. GSA Capital Partners LLP acquired a new stake in Aspen Aerogels during the 1st quarter worth about $1,181,000. Oppenheimer & Co. Inc. purchased a new stake in Aspen Aerogels in the first quarter valued at approximately $388,000. Comerica Bank acquired a new position in Aspen Aerogels in the 1st quarter worth approximately $1,992,000. Healthcare of Ontario Pension Plan Trust Fund raised its position in Aspen Aerogels by 66.7% during the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 80,591 shares of the construction company’s stock worth $1,922,000 after buying an additional 32,243 shares during the last quarter. Finally, Vanguard Group Inc. lifted its stake in Aspen Aerogels by 5.1% during the 1st quarter. Vanguard Group Inc. now owns 3,619,702 shares of the construction company’s stock valued at $63,707,000 after acquiring an additional 175,906 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Aspen Aerogels Company Profile

Aspen Aerogels, Inc designs, develops, manufactures, and sells aerogel insulation products primarily for use in the energy infrastructure and sustainable insulation materials markets in the United States, Asia, Canada, Europe, and Latin America. It operates in two segments, Energy Industrial and Thermal Barrier.